Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI, Inc. (OTCQX: PYNKF) is a commercial-stage medical technology company whose news flow centers on the development, clinical use, and commercialization of its optical coherence tomography (OCT) imaging platforms for cancer surgery. Company updates frequently highlight the adoption of its FDA-cleared Perimeter S-Series OCT system in operating rooms across the United States, including agreements with major health systems and hospitals for tissue visualization during surgery.
News releases describe how surgeons at leading centers are using the S-Series OCT to obtain real-time, cross-sectional visualization of excised tissues at the cellular level, and how this imaging can provide additional insights for intraoperative decision-making. Perimeter also reports on progress with its investigational Perimeter B-Series OCT with Assist AI, a breakthrough-device-designated platform that combines OCT with artificial intelligence and has been evaluated in a pivotal clinical trial supported by a grant from the Cancer Prevention and Research Institute of Texas.
Investors following PYNKF can expect updates on commercial traction for the S-Series, including new hospital installations and systemwide agreements, as well as regulatory milestones related to the B-Series PMA review. The company’s news also covers participation in professional medical conferences, breast surgery forums, and investor events, along with capital raising activities intended to support commercialization and product development.
This news page aggregates Perimeter’s press releases and related coverage so readers can monitor developments in its OCT imaging technology, clinical collaborations, regulatory pathway, and corporate strategy. For those tracking small- and micro-cap medical technology names, the PYNKF news feed offers ongoing insight into how Perimeter is positioning its imaging platforms within cancer surgery and breast care.
Perimeter (OTCQX: PYNKF) unveiled Claire™, an OCT+AI imaging system for intraoperative breast cancer margin assessment, at ASBrS 2026 (April 29–May 3) with live demos at Booth #325.
Claire received FDA PMA in March 2026 as the first AI-enabled U.S. device for this use, offers 10x higher resolution than X-ray/ultrasound at a 2mm imaging depth, and was trained on a library of over 2 million breast OCT images; commercial launch is pending.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and later archived in the company's Investors section under "News/Events."
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported preliminary unaudited Q4 and full-year 2025 results showing record revenue and improved operating performance. FY2025 revenue was approximately $2.3M (up 172% YoY); Q4-2025 revenue was approximately $711K (up 143% YoY). The company received FDA PMA approval for Claire in March 2026 and expects a U.S. commercial launch in Q2-2026. Operating expenses and cash used in operations both improved year-over-year; cash on hand was approximately $2.5M as of December 31, 2025.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will report fourth quarter and full year 2025 results after market close on March 31, 2026 and will host a webcast and conference call at 5:00 pm ET.
The company also entered a warrant cancellation agreement with Social Capital, surrendering 14,466,667 warrants for no consideration, reducing Social Capital's partially‑diluted stake from 30% to 22.3% (non‑diluted stake remains 22.2%).
Perimeter Medical Imaging AI (OTCQX: PYNKF) received FDA premarket approval (PMA) for Claire, the first FDA‑approved AI‑enabled intraoperative imaging device for breast cancer margin assessment. Claire demonstrated 88.1% margin accuracy and a statistically significant reduction in residual cancer; a nationwide launch begins in the coming weeks.
Claire combines patented wide‑field OCT with an AI trained on >2 million OCT images, offers ~10x higher resolution at 2mm depth, has Breakthrough Device designation, and targets an estimated 300,000 annual U.S. breast‑conserving surgeries.
Perimeter Medical Imaging AI (OTCQX: PYNKF) plans to cancel up to 2,175,619 previously issued stock options and re-grant the same number as replacement options exercisable at C$0.30 per share.
The Replacement Options vest in three schedules beginning Jan 1, 2026, retain the Original Options' expiry dates, exclude directors and officers, and are subject to approval as a re-pricing by the TSX Venture Exchange.
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced a systemwide agreement with Intermountain Health on Jan. 8, 2026 to enable deployment of Perimeter's S-Series OCT imaging technology for intraoperative tissue visualization.
The arrangement covers Intermountain Health locations including LDS Hospital in Salt Lake City and American Fork Hospital and permits any of Intermountain's 34 hospitals and 400 clinics across Utah, Idaho, Nevada, Colorado, Montana and Wyoming to acquire the technology. The agreement builds on a prior Development Support Agreement that provided a framework to evaluate the OCT technology and collect data to support Perimeter's AI algorithm development.
Perimeter Medical Imaging AI (OTCQX: PYNKF) closed a C$3.56 million non-brokered private placement on Dec 9, 2025, issuing 19,757,306 units at C$0.18 each.
Each unit includes one common share and one warrant exercisable at C$0.35 for 60 months. Insiders led the financing: CEO Adrian Mendes purchased 11,656,642 units and insider Schiralli purchased 1,111,111 units. The company said net proceeds will support commercialization of the S-Series, product development, working capital and the pending FDA decision on the AI-powered B-Series expected in H1 2026.
Perimeter Medical Imaging AI (OTCQX: PYNKF) announced that HCA HealthONE Rose in Colorado is the first in the state to adopt Perimeter's S-Series OCT wide-field optical coherence tomography for intraoperative tissue visualization.
The S-Series is FDA-cleared for general tissue imaging, offers cellular-level resolution optimized to 2 mm for identifying tissue microstructures, and aims to reduce repeat surgeries by providing intraoperative margin insights previously only available from pathology results that can take up to 10 days.
HCA HealthONE Rose joins Perimeter's expanding commercial footprint while the company awaits a regulatory decision on its next-generation B-Series OCT which pairs OCT with artificial intelligence.
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported Q3 2025 results with continued commercial traction for the FDA-cleared S-Series and ongoing review of the B-Series PMA, which the company expects in H1 2026. Key Q3 metrics: revenue $536,000 (+157% YoY, +6% QoQ), nine-month revenue $1.6M (+88% vs 2024), operating expenses down 34% YoY and 30% QoQ, net loss $2.7M (≈42% improvement YoY), and cash $1.7M. Installed S-Series devices have imaged >3,500 patients (17% increase). The company closed a units offering raising ≈$1.6M and scheduled a conference call today at 5:00 pm ET.